Agenda for Day 2 - Friday September 18th, 2026Friday, September 18, 2026

This session reframes AI-driven conversation intelligence for compliance teams: exploring how automation can continuously monitor voice and chat interactions to detect compliance risks, verify agent acknowledgements, and extract structured evidence to support audits, investigations, and training. Andrew Larty of Authenticx will demonstrate practical use cases, discuss benefits, best practices, and considerations when moving toward automated monitoring.

• Learn all about automation within Compliance programs and the emerging risk areas
• Glean new ideas on where to focus and consolidate resources
• Evaluate current team capabilities against future skill requirements
• How can you best maintain an agile program?

• Best practices for identifying and mitigating Compliance risks when engaging third-party vendors and partners
• Effective monitoring strategies that extend beyond initial due diligence and onboarding
• Examine the benefits and challenges of ongoing monitoring approaches versus point-in-time assessments to optimize your third-party risk management program
• Enterprise risk management – do compliance teams have that responsibility?

• Updates from the DOJ and OIG on free testing- are there implications for diagnostic testing as a whole? What are the anti-kickback risks?
• Analyze implications of recent OIG opinion on one-time genetic test or treatment approval
• What is the current relationship status between diagnostics and labs as a result?
• Inducement risk beyond free testing – copay assistance, patient support and value-added services
• Safe harbor protections and exceptions – when do free testing programs qualify for regulatory protection?

• Explore new go-to market strategies and how to best maintain existing guardrails
• How are commercial and medical relationships evolving?
• Delineate the differences between medical education and sales/promotion and discuss best practices moving forward

• Examining the ongoing debate between federal and state privacy laws and their implications
• Regulatory, privacy and promotional risks raised with the applications of digital therapeutics, wearables, companion apps and RWE collection
• Explore the intersections between telemedicine and privacy
• Addressing the California Consumer Privacy Act (CCPA) and its interplay with sector-specific federal regulations (i.e. HIPAA) - how this impacts the creation of harmonized compliance frameworks

• Practical ways to incorporate Adult Learning Principles into your training program
• Explore outside the box ideas to develop engaging training modules– where can I implement AI?
• Novel approaches to promote retention of materials

• Hear enforcement and programmatic implications for patient‑facing and diagnostic initiatives, covering Patient Speaker/Patient Ambassador programs, free testing and inducement risks (copay assistance, value‑added services), and recent DOJ & OIG enforcement trends with compliance guardrails
• Discover recent legislative and regulatory developments impacting the biopharmaceutical industry such as drug pricing, reimbursement and access